2. Search Result
Search Result
Results for "

reducing body weight

" in MedChemExpress (MCE) Product Catalog:

33

Inhibitors & Agonists

1

Biochemical Assay Reagents

3

Peptides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-U00340
    PPAR agonist 1

    		PPAR Metabolic Disease
    PPAR agonist 1 is an agonist of PPAR α and PPAR γ, used for reducing blood glucose, lipid levels, lowering cholesterol and reducing body weight.
    PPAR agonist 1
  • HY-110107
    GW438014A

    		Neuropeptide Y Receptor Metabolic Disease
    GW438014A is a potent and selective NPY-Y5 receptor antagonist. GW438014A inhibits food intake and reduces body weight gain in obese rodents .
    GW438014A
  • HY-121827
    LH21

    		Cannabinoid Receptor Metabolic Disease
    LH-21 is a potent in vivo neutral cannabinoid CB1 receptor antagonist. LH-21 reduces food intake and body weight gain in obese Zucker rats. , and displays efficacy as a feeding inhibitor .
    LH21
  • HY-153865
    Lotiglipron

    PF-07081532

    		 GCGR Metabolic Disease
    Lotiglipron (PF-07081532) is an orally active GLP-1R agonist. Lotiglipron reduces glucose and body weight, and can be used for research of Type 2 diabetes mellitus (T2DM) .
    Lotiglipron
  • HY-120943
    K-111

    BM 17.0744

    		 PPAR Metabolic Disease
    K-111 (BM-170744) is an oral active PPAR alpha agonist. K-111 show efficacy in improving insulin resistance, reducing body weight, and ameliorating atherogenic dyslipidemia. K-111 can be used for study of type 2 diabetes, dyslipidaemia, obesity and the metabolic syndrome .
    K-111
  • HY-P10745
    Petrelintide

    ZP8396

    		 Amylin Receptor Metabolic Disease
    Petrelintide (ZP8396) is an amylin analogue that shows potential to reduce body weight. Petrelintide can be utilized in diabetes research .
    Petrelintide
  • HY-114690
    PNU-140975

    BVT.3531

    		 Potassium Channel Neurological Disease
    PNU-140975 (BVT.3531) is a novel and potent bioactive compound. PNU-140975 can reduce body weight and activates KATP channel in isolated arcuate neurons in rats .
    PNU-140975
  • HY-157312
    TM38837

    		Cannabinoid Receptor Metabolic Disease
    CB1 antagonist 4 is a inverse agonist of cannabinoid receptor 1 (CB1) with an IC50 of 0.4 nM. CB1 antagonist 4 can reduce body weight, improve plasma inflammatory markers and glucose homeostasis .
    TM38837
  • HY-14753
    Rosonabant

    		Cannabinoid Receptor Cardiovascular Disease Metabolic Disease
    Rosonabant is a selective antagonist for cannabinoid receptor (CB1 receptor), which reduces body weight and improves improves the risk of obesity-related cardiovascular metabolic diseases. Rosonabant exhibits adverse side effect, such as nausea and mental disorder .
    Rosonabant
  • HY-19656
    HMR1426

    		Others Metabolic Disease
    HMR1426 is an orally active, potent gastric emptying inhibitor. HMR1426 reduces food intake and the rate of gastric emptying, decreases body weight and fat mass and shows an anorectic potential in rats. HMR1426 has the potential for obesity research .
    HMR1426
  • HY-165393
    Elaidyl-sulfamide

    N-(9E)-9-Octadecen-1-ylsulfamide

    		 PPAR Metabolic Disease
    Elaidyl-sulfamide (N-(9E)-9-Octadecen-1-ylsulfamide) is a PPARα agonist. Elaidyl-sulfamide reduces body weight gain and food intake and reduces circulating cholesterol levels and increases both glucose and insulin levels. Elaidyl-sulfamide has the potential for the research of complicated obesity .
    Elaidyl-sulfamide
  • HY-167846
    YLIU-4-105-1

    		JAK Cancer
    YLIU-4-105-1 is a Type II JAK2 inhibitor. YLIU-4-105-1 has in vivo pharmacodynamic activity as evidenced by inhibiting pSTAT5, reducing spleen to body weight, and lowering blood reticulocyte counts in a dose-dependent manner .
    YLIU-4-105-1
  • HY-124399
    N-Octadecyl-N'-propyl-sulfamide

    		Endogenous Metabolite PPAR Metabolic Disease
    Peroxisome proliferator-activated receptors (PPARs) play an important role in regulating lipid and glucose metabolism, and oleoylethanolamide (OEA) is a natural ligand for PPARα. N-Octadecyl-N'-propyl-sulfamide is an analog of OEA and a potent activator of PPARα, with selective binding affinity for PPARα (EC50=100 nM, compared to 120 nM for OEA). N-Octadecyl-N'-propyl-sulfamide (10 mg/kg; ip) inhibits food intake and reduces body weight gain in rats. At a dose of 1 mg/kg, N-Octadecyl-N'-propyl-sulfamide induces satiety, thereby reducing food intake, body weight, and plasma triglyceride concentrations in free-feeding Wistar rats and obese Zucker (fa/fa) rats.
    N-Octadecyl-N'-propyl-sulfamide
  • HY-164535
    Maridebart cafraglutide

    AMG 133

    		 GLP Receptor Metabolic Disease
    Maridebart cafraglutide (AMG 133) is an antibody-peptide conjugate acting as a GLP-1 receptor agonist and an antagonist of the GIP receptor. Maridebart cafraglutide reduces body weight and improve metabolic markers in male obese mice and cynomolgus monkeys. Maridebart cafraglutide is promising for research of obesity .
    Maridebart cafraglutide
  • HY-19848
    Cevoglitazar

    LBM-642

    		 PPAR Metabolic Disease
    Cevoglitazar (LBM-642) is an orally active and highly potent PPARα and PPARγ dual agonist. Cevoglitazar can reduce food intake, body weight, and fasting plasma insulin in obese mice and cynomolgus monkeys. Cevoglitazar has the potential for diabetes and obesity-related disorders research .
    Cevoglitazar
  • HY-12191
    A-331440

    		Histamine Receptor Metabolic Disease
    A-331440 is a potent and selective histamine H3 receptor antagonist that regulates neurotransmitter release by inhibiting presynaptic H3 receptors. In preclinical studies involving mice on a high-fat diet, A-331440 demonstrated dose-dependent effects on weight reduction and fat loss. At 5 mg/kg, it effectively decreased body weight comparable to dexfenfluramine, while at 15 mg/kg, it significantly reduced body fat and improved insulin tolerance, similar to mice on a low-fat diet. These findings suggest that A-331440 holds promise as an antiobesity agent by modulating histaminergic pathways involved in food intake and metabolic regulation .
    A-331440
  • HY-130208
    Thiodigalactoside
    3 Publications Verification

    TDG

    		 Galectin Metabolic Disease Inflammation/Immunology Cancer
    Thiodigalactoside (TDG) is an orally active and potent galectin (GAL) inhibitor with Kd values of 24 μM, 49 μM for GAL1 and GAL3, respectively . Thiodigalactoside, a non-metabolizable disaccharide, has anti-inflammatory and anti-cancer activity. Thiodigalactoside dramatically reduces body weight gain in diet-induced obese rats .
    Thiodigalactoside
  • HY-124821
    VA012

    		5-HT Receptor Neurological Disease Metabolic Disease
    VA012 (compound 11) is a positive allosteric modulator (PAM) of the serotonin 5-HT2C receptor. VA012 reduces food intake and body weight gain without causing CNS-related malaise during subchronic administration. VA012 can be utilized in obesity research .
    VA012
  • HY-107727
    BMS-193885 L-Lactic acid

    		Neuropeptide Y Receptor Neurological Disease
    BMS-193885 (L-Lactic acid) is a potent, selective, and brain-penetrant neuropeptide Y1 receptor antagonist. BMS-193885 has a Ki value of 3.3 nM for the neuropeptide Y1 receptor, competitively acts on the neuropeptide Y binding site, and can reduce food intake and body weight through central Y1 inhibition .
    BMS-193885 L-Lactic acid
  • HY-163945
    ZTA-261

    		Thyroid Hormone Receptor Metabolic Disease
    ZTA-261 is a highly selective and low toxic thyroid hormone receptor β subtype (THR-β) agonist (IC50=6.3 nM) that reduces body weight and visceral fat through a liothyronine (HY-A0070A) mediated pathway. ZTA-261 can be used in the study of lipid metabolism and obesity prevalence .
    ZTA-261
  • HY-W127851
    CLA

    Cypridina luciferin analog

    		 Biochemical Assay Reagents Others Cancer
    CLA, or conjugated linoleic acid, is a polyunsaturated fatty acid that occurs naturally in a variety of animal products, such as meat and dairy. It has several potential benefits for human health, including the ability to reduce body fat mass, improve insulin sensitivity, and reduce inflammation. CLA has been extensively studied for its effects on weight loss and muscle growth, as well as its potential role in preventing chronic diseases such as heart disease and cancer. Additionally, it can be taken as a dietary supplement in capsule form.
    CLA
  • HY-14342
    MK-5046
    2 Publications Verification

    		 Bombesin Receptor Metabolic Disease
    MK-5046 is a potent, selective and orally active Bombesin receptor subtype-3 (BRS-3) allosteric agonist with an IC50 and an EC50 value of 27 and 25 nM for hBRS-3, respectively. MK-5046 inhibits food intake and reduces body weight of diet-induced obese (DIO) mouse models. MK-5046 can be used for the research of obesity .
    MK-5046
  • HY-149663
    BMS-986172

    		Acyltransferase Metabolic Disease
    BMS-986172 is an orally active, highly selective MGAT2 inhibitor with an IC50 of 4.6 nM and 20 nM for hMGAT2 and mMGAT2, respectively. BMS-986172 has a T1/2>120 min in vitro assays. BMS-986172 reduces food intake and body weight. BMS-986172 has the potential for metabolic disorders such as obesity and NASH research .
    BMS-986172
  • HY-126969
    C333H

    		Others Metabolic Disease
    C333H is a selective PPARγ modulator with insulin-sensitizing and hypoglycemic activities. C333H exhibits similar insulin-sensitizing effects to thiazolidinediones (TZDs) in diabetic mouse models without significantly increasing body weight or adipose tissue weight. C333H increases circulating high molecular weight adiponectin isoform levels in diabetic db/db mice, reduces serine phosphorylation of PPARγ 273 in brown adipose tissue, and selectively modulates the expression of specific PPARγ target genes in adipose tissue. Express. C333H exhibits weak recruitment of co-activators and weak dissociation of co-repressors in vitro. These properties suggest that C333H may be a potential inhibitor of type 2 diabetes .
    C333H
  • HY-112584
    JBSNF-000088
    3 Publications Verification

    6-Methoxynicotinamide

    		 Others Metabolic Disease
    JBSNF-000088 (6-Methoxynicotinamide), a analog of nicotinamide (NA), is a potent and orally active Nicotinamide N-methyltransferase (NNMT) inhibitor with IC50s of 1.8 µM, 2.8 µM, and 5.0 µM for human NNMT, monkey NNMT and mouse NNMT, respectively. JBSNF-000088 inhibits NNMT activity, reduces MNA levels and drives insulin sensitization, glucose modulation and body weight reduction in animal models of metabolic disease .
    JBSNF-000088
  • HY-155967
    CB1R/AMPK modulator 1

    		AMPK Cannabinoid Receptor Metabolic Disease
    CB1R/AMPK modulator 1 (Compound 38-S) is an orally active CB1R/AMPK modulator, with an Ki of 0.81 nM and an IC50 of 3.9 nM for CB1R. CB1R/AMPK modulator 1 activates AMPK. CB1R/AMPK modulator 1 reduces food intake and body weight, and improves glucose tolerance and insulin sensitivity .
    CB1R/AMPK modulator 1
  • HY-162703
    Lipid-lowering agent-2

    		AMPK Metabolic Disease
    Lipid-lowering agent-2 (Compound 14d) is an orally active lipid-lowering agent with an EC50 of 0.06 μM. Lipid-lowering agent-2 inhibits the lipid synthesis, activates the AMPK signaling pathway, and exhibits anti-obesity effect. Lipid-lowering agent-2 inhibits food intake, improves the glucose metabolism, and reduces the body weight and adipose tissue in high-fat diet (HFD)-induced obese mice .
    Lipid-lowering agent-2
  • HY-161985
    PPARγ-IN-3

    		PPAR Metabolic Disease
    PPARγ-IN-3 (compound 9ga) is a potent and orally active PPARγ inhibitor. PPARγ-IN-3 reduces triglyceride (TG) accumulation with low cytotoxicity. PPARγ-IN-3 preventes the excessive growth of body weight and lessened fat mass as well as liver mass, decreases lipid accumulation in the liver and blood. PPARγ-IN-3 has the potential for the research of diet-induced obesity .
    PPARγ-IN-3
  • HY-100546
    GSK-LSD1

    		Histone Demethylase Infection Metabolic Disease Cancer
    GSK-LSD1 is a LSD1 inhibitor. GSK-LSD1 reduces food intake and body weight, and improves insulin sensitivity and glycemic control in mouse models of obesity. GSK-LSD1 also ameliorates NAFLD. GSK-LSD1 inhibits SARS-CoV-2-triggered cytokine release in COVID-19 PBMCs. GSK-LSD1 also inhibits cancer growth and metastasis .
    GSK-LSD1
  • HY-14342A
    (R)-MK-5046

    		Others Metabolic Disease
    (R)-MK-5046 is the isomer of MK-5046 (HY-14342), and can be used as an experimental control. MK-5046 is a potent, selective and orally active Bombesin receptor subtype-3 (BRS-3) allosteric agonist with an IC50 and an EC50 value of 27 and 25 nM for hBRS-3, respectively. MK-5046 inhibits food intake and reduces body weight of diet-induced obese (DIO) mouse models. MK-5046 can be used for the research of obesity .
    (R)-MK-5046
  • HY-117427
    D5D-IN-326

    		Others Metabolic Disease
    D5D-IN-326 is a selective, orally active delta-5 desaturase (D5D) inhibitor, with IC50s of 72 and 22 nM for rat and human D5D in enzymic and cell-based assays, respectively, has no effect on D6D or D9D activity. D5D-IN-326 reduces insulin resistance and decreases body weight in diet-induced obese C57BL/6J mice .
    D5D-IN-326
  • HY-120828
    Albenatide

    CJC 1134PC

    		 GLP Receptor Metabolic Disease
    Albenatide (CJC 1134PC) is a modified Exendin-4 (HY-13443) analogue conjugated to human recombinant albumin (HRA) in vitro to form a long-acting DPP-4-resistant GLP-1R agonist. Albenatide covalently binds through a low-molecular chemical linker (cys-C13H19O6N3-lys) to the cysteine residue in position 34 of HRA. Albenatide increases cyclic AMP (cAMP) production in vitro. Albenatide reduces glucose excursions, food intake, gastric emptying in wild-type mice and improves glucose tolerance and reduces body weight in high-fat diet mice .
    Albenatide
  • HY-159595
    PCSK9-IN-29

    		LDLR PCSK9 Metabolic Disease Inflammation/Immunology
    PCSK9-IN-29 is a lipid-lowering agent. PCSK9-IN-29 can increase low-density lipoprotein receptor (LDLR) protein expression and decrease PCSK9 protein expression in hepG2 cells. PCSK9-IN-29 can reduce the levels of serum LDL-C, TC, and liver enzyme ALT in crab eating macaques fed a high-fat diet, lower body weight and fat, and increase bone mineral content. PCSK9-IN-29 can be used for research on non-alcoholic fatty liver disease and obesity .
    PCSK9-IN-29

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: